288 related articles for article (PubMed ID: 22354465)
1. Apixaban: an oral direct factor-xa inhibitor.
Jiménez D; Yusen RD; Ramacciotti E
Adv Ther; 2012 Mar; 29(3):187-201. PubMed ID: 22354465
[TBL] [Abstract][Full Text] [Related]
2. The role of apixaban for venous and arterial thromboembolic disease.
Prom R; Spinler SA
Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
[TBL] [Abstract][Full Text] [Related]
3. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ
N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123
[TBL] [Abstract][Full Text] [Related]
4. Apixaban for the prevention of stroke in atrial fibrillation.
Littrell R; Flaker G
Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
[TBL] [Abstract][Full Text] [Related]
5. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
6. [Apixaban: pharmacology and action profile].
Gassanov N; Caglayan E; Er F
Dtsch Med Wochenschr; 2012 Jan; 137(4):138-41. PubMed ID: 22259168
[TBL] [Abstract][Full Text] [Related]
7. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
8. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
[TBL] [Abstract][Full Text] [Related]
9. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of apixaban : where do we stand in 2013?
de Souza Brito F; Lopes RD; Alexander JH
Expert Opin Drug Saf; 2013 Jul; 12(4):559-67. PubMed ID: 23662974
[TBL] [Abstract][Full Text] [Related]
11. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
12. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
Huang J; Cao Y; Liao C; Wu L; Gao F
Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
[TBL] [Abstract][Full Text] [Related]
13. [Apixaban].
Konstantinides S; Münzel T
Hamostaseologie; 2012; 32(3):203-11. PubMed ID: 22739932
[TBL] [Abstract][Full Text] [Related]
14. Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation.
Lam S
Cardiol Rev; 2013; 21(4):207-12. PubMed ID: 23535530
[TBL] [Abstract][Full Text] [Related]
15. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
[TBL] [Abstract][Full Text] [Related]
16. Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Li XM; Sun SG; Zhang WD
Chin Med J (Engl); 2012 Jul; 125(13):2339-45. PubMed ID: 22882859
[TBL] [Abstract][Full Text] [Related]
17. Apixaban in acute coronary syndromes.
Karthikeyan G; Eikelboom JW
Cardiovasc Ther; 2011 Oct; 29(5):285-90. PubMed ID: 20553278
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Martin MT; Nutescu EA
Curr Med Res Opin; 2011 Nov; 27(11):2123-31. PubMed ID: 21942466
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
[TBL] [Abstract][Full Text] [Related]
20. Apixaban: a novel oral inhibitor of factor Xa.
Nutescu E
Am J Health Syst Pharm; 2012 Jul; 69(13):1113-26. PubMed ID: 22722590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
